Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally

Stoke Therapeutics is an early-stage biotechnology company leveraging its proprietary Targeted Augmentation of Nuclear Gene Output platform to develop novel RNA-based therapies for severe genetic diseases. The company’s strategy centers on advancing its clinical pipeline and forging partnerships to accelerate commercialization opportunities. With a focused approach on rare neurological disorders, Stoke Therapeutics positions itself as an innovator within the biopharmaceutical sector.It serves patients affec ...